financetom
Business
financetom
/
Business
/
SBI Life Insurance sets aside higher COVID claim amount this year at Rs 183 crore
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
SBI Life Insurance sets aside higher COVID claim amount this year at Rs 183 crore
Jun 30, 2021 2:35 AM

SBI Life Insurance saw a slowdown in their group business in May. The company only registered a growth of 1.35 percent in new business premium, owing to the lockdown.

To understand the COVID claim picture after the brutal second wave, CNBC-TV18 spoke to Mahesh Kumar Sharma, MD & CEO of SBI Life Insurance.

Sharma said, “Last year, we had much more COVID claims in the second half than the first half. What we are doing is that we have changed our mortality assumptions and we have also set aside a higher amount. Last time we had set aside some amount, this time we have set aside a higher amount for any spike in COVID claims. So that is one of the things that we have done. We have set aside Rs 183 crore as compared to last year’s Rs 40 crore, which was increased to Rs 70 crore. This year we have taken Rs 183 crore as a conservative figure.”

He added, “Our expectation is that we will be back to normal if this is the way things proceed on the vaccination front.”

On claims, he said, “If you look at the trend from last year, I would agree with my peers out there that depending on the product, there could be some spikes here and there.”

On new business premium growth, Sharma said, “We have an internal plan and we go according to our internal estimates and we end the year very strong. I am very confident that we will be able to achieve our targets.”

On VNB, he said, “Value of new business, if you see the trend over the last year 3-4 years the growth has been very steady and we have been able to grow new businesses steadily year-after-year. I am very confident about our ability to keep growing.”

For full management commentary, watch the video.

(Edited by : Dipika)

First Published:Jun 30, 2021 11:35 AM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ncino Insider Sold Shares Worth $375,000, According to a Recent SEC Filing
Ncino Insider Sold Shares Worth $375,000, According to a Recent SEC Filing
Oct 24, 2024
04:29 PM EDT, 10/23/2024 (MT Newswires) -- William J Ruh, Director, on October 21, 2024, sold 10,000 shares in Ncino ( NCNO ) for $375,000. Following the Form 4 filing with the SEC, Ruh has control over a total of 255,741 shares of the company, with 29,540 shares held directly and 226,201 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1902733/000190273324000167/xslF345X05/wk-form4_1729714629.xml Price: 37.59, Change:...
Newmont Q3 Adjusted Earnings, Sales Rise -- Shares Fall After-Hours
Newmont Q3 Adjusted Earnings, Sales Rise -- Shares Fall After-Hours
Oct 24, 2024
04:41 PM EDT, 10/23/2024 (MT Newswires) -- Newmont ( NEM ) reported Q3 adjusted earnings late Wednesday of $0.81 per diluted share, up from $0.36 a year earlier. Analysts polled by Capital IQ expected $0.86. Sales for the quarter ended Sept. 30 were $4.61 billion, down from $2.49 billion a year earlier. Analysts polled by Capital IQ expected $4.67 billion....
Las Vegas Sands misses third-quarter profit estimates on weak Macao business
Las Vegas Sands misses third-quarter profit estimates on weak Macao business
Oct 24, 2024
Oct 23 (Reuters) - Las Vegas Sands ( LVS ) missed analysts' expectations for quarterly profit on Wednesday, hit by an ongoing renovation at its Londoner casino in Macao and lower-than-expected per table income in Singapore. The casino operator posted a quarterly profit of 44 cents per share. Analysts on average had expected a profit of 53 cents per share,...
US CDC advisers recommend expanding pneumococcal vaccination to adults aged 50-64
US CDC advisers recommend expanding pneumococcal vaccination to adults aged 50-64
Oct 24, 2024
Oct 23 (Reuters) - Advisers to the Centers for Disease Control and Prevention on Wednesday recommended expanding the use of vaccines to adults between 50-64 years to protect against pneumococcal disease. The CDC currently recommends all children younger than 5 and all adults 65 years or older get vaccinated for the disease. Vaccination is also recommended for some children and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved